To further show that the superior in vivo efficacy of MCJ-deficient CD8 CAR-T cells was due to a better effector function of these cells we performed ex vivo killing assay with CAR-T cells recovered from the tumor site (i.e., bone marrow). The gene discussed is CD8A; the disease is neoplasm.